<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124241">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01718873</url>
  </required_header>
  <id_info>
    <org_study_id>OBELICS</org_study_id>
    <secondary_id>2011-004997-27</secondary_id>
    <nct_id>NCT01718873</nct_id>
  </id_info>
  <brief_title>Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer</brief_title>
  <acronym>OBELICS</acronym>
  <official_title>Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if giving bevacizumab prior to chemotherapy
      compared to giving bevacizumab at the same time as chemotherapy improves patient overall
      response to treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>number of objective responses</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worst grade toxicity per patient</measure>
    <time_frame>evaluated every 2 weeks up to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in quality of life</measure>
    <time_frame>measured at baseline, 12 weeks, and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>evaluation of prognostic and predictive factors</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>circulating endothelial cell counts,  cytokines, antiangiogenic factors, single nucleotide polymorphisms of VEGF, leukocyte count 24 hours after administration of bevacizumab, and mRNA  will be evaluated in blood samples of participating consenting patients, for correlation with clinical outcomes of patients</description>
  </other_outcome>
  <other_outcome>
    <measure>change in metabolic tumor volume</measure>
    <time_frame>11 days from first day of first cycle of chemotherapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>measured by PET scan</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>bevacizumab before chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab administered 4 days before each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bevacizumab with chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab administered on the first day of each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/kg every 2 weeks for up to 24 weeks.  After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.</description>
    <arm_group_label>bevacizumab before chemotherapy</arm_group_label>
    <arm_group_label>bevacizumab with chemotherapy</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85mg/m2 IV every 2 weeks for up to 24 weeks</description>
    <arm_group_label>bevacizumab before chemotherapy</arm_group_label>
    <arm_group_label>bevacizumab with chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levo-folinic acid</intervention_name>
    <description>200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks</description>
    <arm_group_label>bevacizumab before chemotherapy</arm_group_label>
    <arm_group_label>bevacizumab with chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)</description>
    <arm_group_label>bevacizumab before chemotherapy</arm_group_label>
    <arm_group_label>bevacizumab with chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)</description>
    <arm_group_label>bevacizumab before chemotherapy</arm_group_label>
    <arm_group_label>bevacizumab with chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of colorectal adenoma carcinoma

          -  Stage IV disease

          -  Presence of at least one measurable target lesion (according to RECIST), and not
             previously radiated.

          -  Age  ≥ 18 e ≤ 75 years

          -  ECOG Performance status 0-1

          -  Life expectancy &gt;3 months

          -  Adequate recovery from surgery, with at least 28 days from surgery to date of
             pre-study biopsy.

          -  Adequate contraception for male and female patients of child bearing potential

          -  informed consent

        Exclusion Criteria:

          -  More than one previous line of therapy for metastatic disease

          -  Prior treatment with bevacizumab or oxaliplatin (previous treatment with irinotecan,,
             cetuximab, fluoropyrimidine, folic acid are permitted)

          -  Primary tumor that is stenosing and/or that infiltrates the entire thickness of the
             intestinal wall

          -  Regular use of NSAIDs or aspirin

          -  Bleeding disorders or coagulopathy

          -  Concurrent anticoagulant therapy

          -  Suspected or cerebral metastases (to verify in the presence of symptoms)

          -  Neutrophils &lt; 2000 / mm3, platelets &lt; 100,000 / mm3, hemoglobin &lt; 9g/dl

          -  Creatinine &gt; 1.5 times the upper normal limit

          -  GOT and/or GPT &gt; 2.5 times the upper normal limit, bilirubin &gt; 1.5 times the upper
             normal limit in absence of liver metastases

          -  GOT and/or GPT &gt; 5 times the upper normal limit, bilirubin &gt; 3 times the upper normal
             limit in presence of liver metastases

          -  Other co-existing malignancies or malignancies diagnosed within the last 5 years with
             the exception of basal and squamous cell carcinoma or cervical cancer in situ

          -  Congestive heart failure, ischemic coronary events within past 12 months,
             uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension

          -  Active or uncontrolled infection

          -  Any concomitant condition that, in the investigator's opinion, would contraindicate
             the use of any of the study drugs

          -  Pregnancy or lactation

          -  Central nervous system disorders or peripheral neuropathy &gt; grade 1 (CTCAE v. 4.0)

          -  Inability to comply with follow up procedures of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Avallone, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Avallone, M.D.</last_name>
    <phone>+39 081 5903629</phone>
    <email>avalloneantonio@libero.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>October 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <keyword>stage IV</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
